2014 Patient Seminar (Houston, TX)
Update on Latest Treatment Opportunities
HCL Research
Presenter:
Dr. Claire Dearden, The Royal Marsden, United Kingdom (Presentation Slides and Audio)
Clinical Trials at the National Institutes of Health
Presenter:
Dr. Robert J. Kreitman, NIH, USA (Presentation Slides and Audio)
Vemurafenib Research
Presenter:
Dr. Brunangelo Falini, University of Perugia, Italy (Presentation Slides and Audio)
Vemurafenib Trial
Presenter:
Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA (Presentation Slides and Audio)
Ibrutinib Trial
Presenter:
Dr. Michael R. Grever, The Ohio State University Wexner Medical Center, USA (Presentation Slides and Audio)
Cladribine and Rituximab Trial
Presenter:
Dr. Farhad Ravandi, MD Anderson Cancer Center, USA (Presentation Slides and Audio)
Question and Answer Session
What is the definition of Partial Remission (PR), Complete Remission (CR) and Minimal Residual Disease (MRD)? (Audio)
Speakers:
Dr. Michael R. Grever, The Ohio State Wexner Medical Center, USA
Dr. Farhad Ravandi, MD Anderson Cancer Center, USA
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Is the BRAF mutation in all of our cells? (Audio)
Speaker:
Dr. Brunangelo Falini, University of Perugia, Italy
Are you more likely to develop a second malignancy with HCL? (Audio)
Speakers:
Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA
Dr. Robert J. Kreitman, National Institutes of Health, USA
Is there a higher incidence of HCL in certain patient populations or geographies? (Audio)
Speakers:
Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA
Dr. Robert J. Kreitman, National Institutes of Health, USA
Dr. Farhad Ravandi, MD Anderson Cancer Center, USA
Is Vemurafenib an appropriate treatment for Minimal Residual Disease? (Audio)
Speaker:
Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA
Does the amount of hairy cells in your system predict your response to treatment? (Audio)
Speaker:
Dr. Martin S. Tallman, M.D., Memorial Sloan-Kettering Cancer Center
Is fatigue related to HCL and an indication of the potential for treatment? (Audio)
Speaker:
Dr. Farhad Ravandi, M.D., MD Anderson Cancer Center
If you have an intolerance to purine analogs (Cladribine, Pentostatin, etc.), does it mean you are allergic or have a poor response to treatment? (Audio)
Speaker:
Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA
Do we know what causes the “hairy” projections in a hairy cell? (Audio)
Speaker:
Dr. Brunangelo Falini, University of Perugia, Italy
What are the latest treatment opportunities for HCL-v and how does HCL-v differ from HCL? (Audio)
Speaker:
Dr. Robert J. Kreitman, National Institutes of Health, USA
Is a drop in cholesterol associated with HCL? (Audit)
Speaker:
Dr. Martin S. Tallman, Memorial Sloan-Kettering Cancer Center, USA
Should you get irradiated blood and what about vaccinations? (Audio)
Speaker:
Dr. Claire Dearden, The Royal Marsden, United Kingdom
Is it common to use prophylaxis to fight infection during treatment? (Audio)
Speakers:
Dr. Michael R. Grever, The Ohio State Wexner Medical Center, USA
Dr. Claire Dearden, The Royal Marsden, USA
Dr. Farhad Ravandi, MD Anderson Cancer Center, USA